Molecules

rhPSMA-7.3

Target PSMAClass Radiohybrid small molecule (urea, SiFA, DOTAGA)Other names flotufolastat

18ongoing trials
1radiolabelled forms
1approved products
72publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C63H99FN12O25Si
Molar mass (g/mol)
1,471.6
Exact mass (Da)
1,470.6598
H-bond donors
17
H-bond acceptors
30
Rotatable bonds
45
Heavy atoms
102
InChIKey
QMGJNAVROCDAIW-YNVJYXMMSA-N
PubChem record
CID 149063248 ↗
IUPAC name
(2S)-2-[[(1S)-1-carboxy-4-[[(1R)-1-carboxy-4-[[4-[[(5R)-5-carboxy-5-[[(2R)-2-[[(4S)-4-carboxy-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]butanoyl]amino]-3-[[4-[ditert-butyl(fluoro)silyl]benzoyl]amino]propanoyl]amino]pentyl]amino]-4-oxobutanoyl]amino]butyl]amino]-4-oxobutyl]carbamoylamino]pentanedioic acid
SMILES
CC(C)(C)[Si](C1=CC=C(C=C1)C(=O)NC[C@H](C(=O)N[C@H](CCCCNC(=O)CCC(=O)NCCC[C@H](C(=O)O)NC(=O)CC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)NC(=O)CC[C@@H](C(=O)O)N2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)(C(C)(C)C)F

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁸F]rhPSMA-7.3 Syntheses and QC ↗Imaging1,470.618Phase 3Posluma US

Ongoing trials · 18Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
[18F]rhPSMA-7.3 (flotufolastat)NCT05678322 · Prostate – localised / recurrencePhase 3Active, not recruitingNYU Langone Health1
[18F]rhPSMA-7.3 (flotufolastat)NCT07593079 · Prostate – localised / recurrencePhase 2Not yet recruitingWashington University School of Medicine1
ECLIPSE · [18F]rhPSMA-7.3 (flotufolastat)NCT07185165 · Prostate – otherPhase 2RecruitingJonsson Comprehensive Cancer Center1
[18F]rhPSMA-7.3 (flotufolastat)NCT06617481 · Prostate – localised / recurrencePhase 2RecruitingAdventHealth1
[18F]rhPSMA-7.3 (flotufolastat)NCT07220720 · Prostate – otherPhase 2RecruitingUniversity of Florida1
[18F]rhPSMA-7.3 (flotufolastat)NCT07285057 · Prostate – otherPhase 2RecruitingIcahn School of Medicine at Mount Sinai1
[18F]rhPSMA-7.3 (flotufolastat)NCT05779943 · Prostate – localised / recurrencePhase 2Active, not recruitingEmory University1
[18F]rhPSMA-7.3 (flotufolastat)NCT06865768 · Prostate – otherPhase 2RecruitingEmory University1
[18F]rhPSMA-7.3 (flotufolastat)NCT07568756 · Prostate – otherPhase 2Not yet recruitingUniversity of California, Irvine1
[18F]rhPSMA-7.3 (flotufolastat)NCT06813898 · Prostate – otherPhase 1RecruitingNorthwestern University1
[18F]rhPSMA-7.3 (flotufolastat)NCT05852041 · Prostate – otherPhase 1RecruitingNorthwestern University1
[18F]rhPSMA-7.3 (flotufolastat)NCT07149831 · Prostate – otherPhase 1RecruitingSinotau Pharmaceutical Group1
[18F]rhPSMA-7.3 (flotufolastat)NCT07164027 · Prostate – otherPhase 1RecruitingJonsson Comprehensive Cancer Center1
[18F]rhPSMA-7.3 (flotufolastat)NCT07115277 · Prostate – localised / recurrenceNo phaseRecruitingSinotau Pharmaceutical Group1
[18F]rhPSMA-7.3 (flotufolastat)NCT06389786 · Prostate – localised / recurrenceNo phaseRecruitingMayo Clinic1
SCOUT · [18F]rhPSMA-7.3 (flotufolastat)NCT07011342 · Prostate – otherNo phaseRecruitingHackensack Meridian Health1
[18F]rhPSMA-7.3 (flotufolastat)NCT06479187 · Prostate – hormone-sensitiveNo phaseActive, not recruitingBrigham and Women's Hospital1
[18F]rhPSMA-7.3 (flotufolastat)NCT06580015 · Prostate – otherNo phaseActive, not recruitingCity of Hope Medical Center1

PublicationsAll publications in PubMed ↗

72 publications in PubMed for the query below; the most recent:

"rhPSMA-7.3"[tiab] OR flotufolastat[tiab] OR "rhPSMA-7"[tiab]

  1. Detection rate of PSMA PET MRI (18 F-Flotufolastat) at the onset of biochemical recurrence following radical prostatectomy EJNMMI Rep, 2026
  2. Outcome Prediction After [(177)Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [(68)Ga]Ga-PSMA-11 PET-Based Model with [(18)F]F-Flotufolastat J Nucl Med, 2026
  3. Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined (18)F-Flotufolastat PSMA PET and mpMRI J Nucl Med, 2026
  4. Head-to-Head (18)F-rhPSMA-7.3 and (18)F-PSMA-1007 PET/CT in Recurrent Prostate Cancer: Pulmonary and Nodal Uptake as a Diagnostic Challenge Diagnostics (Basel), 2026
  5. Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis Radiol Imaging Cancer, 2026
  6. Prognostic Value of [(18)F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer J Nucl Med, 2026
  7. Value of a repeat (18)F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy Eur J Nucl Med Mol Imaging, 2026
  8. Superior Diagnostic Yield of 18 F-rhPSMA-7.3 Compared With 18 F-DCFPyL PET/CT for the Detection of Recurrent Prostate Cancer Clin Nucl Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

rhPSMA-7.3. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/rhpsma-7-3/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.